Literature DB >> 27746989

Has lobe-specific nodal dissection for early-stage non-small lung cancer already become standard treatment?

Tomohiro Maniwa1, Ken Kodama1.   

Abstract

Entities:  

Year:  2016        PMID： 27746989      PMCID： PMC5059312          DOI： 10.21037/jtd.2016.09.15

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  Radical lobectomy.

Authors:  W G CAHAN
Journal:  J Thorac Cardiovasc Surg       Date:  1960-05       Impact factor: 5.209

Review 2.  Lymph node dissection for lung cancer: significance, strategy, and technique.

Authors:  Shun-ichi Watanabe; Hisao Asamura
Journal:  J Thorac Oncol       Date:  2009-05       Impact factor: 15.609

3.  Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis.

Authors:  Chi-Fu Jeffrey Yang; Arvind Kumar; Brian C Gulack; Michael S Mulvihill; Matthew G Hartwig; Xiaofei Wang; Thomas A D'Amico; Mark F Berry
Journal:  J Thorac Cardiovasc Surg       Date:  2015-12-21       Impact factor: 5.209

4.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

5.  A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer.

Authors:  Yi long Wu; Zhi-fan Huang; Si-yu Wang; Xue-ning Yang; Wei Ou
Journal:  Lung Cancer       Date:  2002-04       Impact factor: 5.705

6.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.

Authors:  Paul De Leyn; Christophe Dooms; Jaroslaw Kuzdzal; Didier Lardinois; Bernward Passlick; Ramon Rami-Porta; Akif Turna; Paul Van Schil; Frederico Venuta; David Waller; Walter Weder; Marcin Zielinski
Journal:  Eur J Cardiothorac Surg       Date:  2014-02-26       Impact factor: 4.191

7.  Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection.

Authors:  M Okada; N Tsubota; M Yoshimura; Y Miyamoto
Journal:  J Thorac Cardiovasc Surg       Date:  1998-12       Impact factor: 5.209

8.  Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer.

Authors:  Morihito Okada; Toshihiko Sakamoto; Tsuyoshi Yuki; Takeshi Mimura; Kei Miyoshi; Noriaki Tsubota
Journal:  Ann Thorac Surg       Date:  2006-03       Impact factor: 4.330

9.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer.

Authors:  P Misthos; E Sepsas; K Athanassiadi; S Kakaris; I Skottis
Journal:  Eur J Cardiothorac Surg       Date:  2004-04       Impact factor: 4.191
View more
  1 in total

1.  Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations.

Authors:  Tomohiro Maniwa; Yasushi Shintani; Jiro Okami; Yoshihisa Kadota; Yukiyasu Takeuchi; Koji Takami; Hideoki Yokouchi; Eiji Kurokawa; Ryu Kanzaki; Yasushi Sakamaki; Hiroyuki Shiono; Teruo Iwasaki; Kiyonori Nishioka; Ken Kodama; Meinoshin Okumura
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.